Food poisoning: Selective isolation medium for Staphylococcus aureus 'Baird-Parker agar'
Reliable food safety management, manufactured in domestic factories under a global brand, recommended by international standards ISO6888, AOAC, and BAM methods.
"Baird Parker Agar" is a selective isolation medium for Staphylococcus aureus recommended in the food proposal No. 0729-4 from July 2015, which revised the testing methods for Staphylococcus aureus as specified in the standards for food and food additives. This product contains sodium pyruvate to promote the growth of staphylococci, while tellurite salts suppress many other bacterial species, and when potassium tellurite is reduced, it causes the colonies of staphylococci to turn black. 【Features】 ■ Recommended by international standards such as ISO6888, AOAC, and BAM methods ■ Manufactured in our domestic factory *For more details, please refer to the catalog. Feel free to contact us with any inquiries.
Inquire About This Product
basic information
【Composition per 1L of purified water】 Casein peptone: 10.0g Meat extract: 5.0g Yeast: 1.0g Glycine: 12.0g Sodium pyruvate: 10.0g Lithium chloride: 5.0g Agar: 20.0g Potassium tellurite: 0.1g 35% concentration egg yolk liquid: 28.5mL pH 7.2±0.2 【Packaging Units】 ■ Fresh medium (newly released) * domestically produced ・BD BBL Baird-Parker agar medium 20 plates, 100 plates ■ Related powdered medium (currently on sale) ・BD Difco Baird-Parker agar base medium 500g * For more details, please refer to the catalog. Feel free to contact us with any inquiries.
Price range
Delivery Time
Applications/Examples of results
[Purpose] It is used as a selective isolation medium for Staphylococcus aureus in food.
Line up（2）
| Model number | overview |
|---|---|
| 252486 | BD BBL Baird Parker Agar Medium (20 sheets) |
| 252487 | BD BBL Baird Parker Agar Medium (100 sheets) |
catalog（1）
Download All Catalogs
Company information
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.
![[Case Study on Culture Media] Establishing a Liquid Culture Media Supply System for a Major Biopharmaceutical Company](https://image.mono.ipros.com/public/default/object/noimage_l.gif?w=280&h=280)
